111
Participants
Start Date
December 31, 2008
Primary Completion Date
January 31, 2012
Study Completion Date
August 31, 2012
CS7017 tablets
CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
Paclitaxel
Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks
Carboplatin
IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
Placebo Tablets
Placebo tablets matching CS-7017 tablets
Penn State Milton Hershey Cancer Center, Hershey
Georgetown Univ. Medical Center, Washington D.C.
Harbor View Cancer Center, Baltimore
Eastern Virginia Medical School, Norfolk
Southern Illinois Hematology/Oncology, Centralia
Michiana Hematology-Oncology, South Bend
Rush University Medical Center, Chicago
Signal Point Clinical Research Center, Middletown
University Colorado Cancer Center, Aurora
Oncomed SRL, Timișoara
Hemato-Oncology Clinic, Vedanta, Gujarat
Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca
Pentagon Research, Aundh
Shatabdi Super Specialty Hospital, Nashik
Kidwai Memorial Institute of Oncology, Bangalore
Apollo Specialty Hospital, Chennai
Orchid Nursing Home, Kolkata
Massachusetts General Hospital, Boston
Meenakshi Mission Hospital, Madurai
Ruby Hall Clinic, Pune
Noble Hospital, Pune
Oddzial Chemioterapii ZOZ MSWiA, Olsztyn
Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii, Poznan
Specjalistyczny Szpital im. Prof. Alfresa Sokolowskiego, Szczecin
Spitalul Municipal Ploiesti, Ploieşti
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu, Bucharest
Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca
Centrul de Oncologie Medicala, Iași
Lead Sponsor
Daiichi Sankyo
INDUSTRY